Tarsus Pharmaceuticals (TARS) Stock Statistics & Valuation Metrics

Tarsus Pharmaceuticals has a market cap or net worth of $2.72B. The enterprise value is $2.68B.

Tarsus Pharmaceuticals has 43,023,960 shares outstanding. The number of shares has decreased by -2.65% in one year.

Tarsus Pharmaceuticals’s return on equity (ROE) is -0.19 and return on invested capital (ROIC) is -16.64%.

The current PE Ratio of Tarsus Pharmaceuticals is ―. Tarsus Pharmaceuticals’s PEG ratio is 1.07.

In the last 12 months, Tarsus Pharmaceuticals had revenue of 451.36M and earned -66.42M in profits. Earnings per share was -1.59.

In the last 12 months, operating cash flow was -16.45M and capital expenditures -15.09M, giving a free cash flow of -31.54M billion.

Tarsus Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―

Tarsus Pharmaceuticals upcoming earnings date is Aug 6, 2026, After Close (Confirmed).

Tarsus Pharmaceuticals as a current ratio of 3.85, with Debt / Equity ratio of 25.41%

In the past 12 months, Tarsus Pharmaceuticals has paid 2.06M in taxes.

Tarsus Pharmaceuticals EV to EBITDA ratio is -62.14, with an EV/FCF ratio of -149.32.

Tarsus Pharmaceuticals has $388.73M in cash and marketable securities with $88.68M in debt, giving a net cash position of $300.06M billion.

Gross margin is 90.44%, with operating margin of -15.72%, and net profit margin of -14.72%.

The average price target for Tarsus Pharmaceuticals is $95.17, which is 11.43% higher than the current price. The consensus rating is Strong Buy